AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20386339 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistation proprioceptive exercise program
Number of subjects: 232
Study 20386339 — intervention group
Group type: COMPARATOR
Intervention: Normal workout routines (Control)
Number of subjects: 232
Study 18227295 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific heparin concentration-based protocol
Number of subjects: 25
Study 18227295 — intervention group
Group type: COMPARATOR
Intervention: Standard weight-based heparin dose (400 U/kg)
Number of subjects: 25
Study 15707467 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis) Turbuhaler 4.5 microg
Number of subjects: 18124
Study 15707467 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 microg
Number of subjects: 18124
Study 14689390 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 76
Study 14689390 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing care plans
Number of subjects: 76
Study 10365879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 35
Study 10365879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7491881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in aspartame
Number of subjects: 48
Study 7491881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in sucrose
Number of subjects: 48
Study 7491881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in saccharin
Number of subjects: 48
Study 7491881 — intervention group
Group type: COMPARATOR
Intervention: Baseline hemolysate samples
Number of subjects: 48
Study 7491881 — intervention group
Group type: EXPERIMENTAL
Intervention: One subject with low hydrolase activity
Number of subjects: 48
Study 1962778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for stage II and IIIA nonsquamous cancer
Number of subjects: 0
Study 1962778 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy for stage I disease
Number of subjects: 0
Study 1962778 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiation therapy for stage II and IIIA squamous cell carcinoma
Number of subjects: 0
Study 6448429 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (500 mg initially, followed by 250 mg as needed, max 1250 mg daily)
Number of subjects: 26
Study 6448429 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 26
Study 30180057 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + CTA
Number of subjects: 2831
Study 30180057 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 2831
Study 27823703 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n=24)
Number of subjects: 45
Study 27823703 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 45
Study 25230288 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention counseling intervention delivered by lay counselors using motivational interviewing strategies based on the Information‐Motivation‐Behavioral (IMB) Skills model during routine clinical care.
Number of subjects: 1891
Study 25230288 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care counseling.
Number of subjects: 1891
Study 22218627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational materials and a fecal immunochemical test (FIT)
Number of subjects: 373
Study 22218627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational materials and a fecal immunochemical test (FIT) plus a telephone call
Number of subjects: 373
Study 20408059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based TC (MBTC) intervention
Number of subjects: 393
Study 20408059 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic community (TC) control group
Number of subjects: 393
Study 17565285 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar odor (vanillin)
Number of subjects: 44
Study 17565285 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar odor
Number of subjects: 44
Study 17565285 — intervention group
Group type: COMPARATOR
Intervention: No odor
Number of subjects: 44
Study 17565285 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar odor learned via mother
Number of subjects: 44
Study 17565285 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar odor learned via crib
Number of subjects: 44
Study 16111600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic dose assessment (I-FL)
Number of subjects: 26
Study 16111600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic dose assessment (I-FL) for I-125
Number of subjects: 26
Study 16111600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic dose assessment (I-FL) for Pd-103
Number of subjects: 26
Study 11825631 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin administration (SC)
Number of subjects: 62
Study 11825631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion (IV)
Number of subjects: 62
Study 11825631 — intervention group
Group type: COMPARATOR
Intervention: Routinely managed group (RM)
Number of subjects: 62
Study 10451565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC) 125 mg
Number of subjects: 0
Study 10451565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (I) 400 mg
Number of subjects: 0
Study 10451565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 8737333 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation in the GUM clinic
Number of subjects: 98
Study 8737333 — intervention group
Group type: COMPARATOR
Intervention: Consultation in the FPC
Number of subjects: 98
Study 8737333 — intervention group
Group type: EXPERIMENTAL
Intervention: GUM testing in the GUM clinic
Number of subjects: 98
Study 8737333 — intervention group
Group type: COMPARATOR
Intervention: GUM testing in the FPC
Number of subjects: 98
Study 1878611 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell activity
Number of subjects: 90
Study 1878611 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 90
Study 7128186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (200 mg)
Number of subjects: 8
Study 7128186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30903885 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL)
Number of subjects: 300
Study 30903885 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 300
Study 28282789 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab and panitumumab (arm I)
Number of subjects: 297
Study 28282789 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo (arm II)
Number of subjects: 297
Study 26937005 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training group
Number of subjects: 100
Study 26937005 — intervention group
Group type: COMPARATOR
Intervention: Active-training control group
Number of subjects: 100
Study 24635773 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based early goal-directed therapy (EGDT)
Number of subjects: 1341
Study 24635773 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based standard therapy
Number of subjects: 1341
Study 24635773 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1341
Study 24635773 — intervention group
Group type: COMPARATOR
Intervention: Protocol-based EGDT vs. usual care
Number of subjects: 1341
Study 24635773 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based EGDT vs. protocol-based standard therapy
Number of subjects: 1341
Study 24635773 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1341
Study 23082174 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS at 2 mA for 20 minutes
Number of subjects: 100
Study 23082174 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS at 2 mA for 20 minutes
Number of subjects: 100
Study 20947305 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (20mg p.o)
Number of subjects: 24
Study 20947305 — intervention group
Group type: EXPERIMENTAL
Intervention: random/matched alternate version of the GMLT
Number of subjects: 24
Study 20947305 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 24
Study 20947305 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 16998094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (300 mg/d)
Number of subjects: 489
Study 16998094 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d)
Number of subjects: 489
Study 16998094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 16266416 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet intervention for older patients to prepare for consultations and outreach visit to GPs.
Number of subjects: 263
Study 16266416 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 263
Study 12151034 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8S 10 microg
Number of subjects: 0
Study 12151034 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8S 20 microg
Number of subjects: 0
Study 12151034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10453446 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 0
Study 10453446 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 8519046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 12
Study 8519046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12
Study 8519046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3476241 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive Amalgam Restorations (EAR)
Number of subjects: 269
Study 3476241 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator influence
Number of subjects: 269
Study 3476241 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention methods
Number of subjects: 269
Study 3476241 — intervention group
Group type: EXPERIMENTAL
Intervention: Side location of the tooth
Number of subjects: 269
Study 3476241 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of the restoration
Number of subjects: 269
Study 30483710 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 45
Study 30483710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 45
Study 30483710 — intervention group
Group type: EXPERIMENTAL
Intervention: M3
Number of subjects: 45
Study 26944539 — intervention group
Group type: COMPARATOR
Intervention: 2-g progesterone intravaginal device on Day -23
Number of subjects: 570
Study 26944539 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of equine chorionic gonadotropin (eCG)
Number of subjects: 570
Study 26944539 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended progesterone treatment combined with eCG
Number of subjects: 570
Study 23768612 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 30 g
Number of subjects: 11
Study 23768612 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein Protein (CP) 30 g
Number of subjects: 11
Study 23768612 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) 33 g
Number of subjects: 11
Study 23768612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 22439807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (TU) four times/year for 36 months
Number of subjects: 60
Study 22439807 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched hypogonadal men with MS)
Number of subjects: 60
Study 21084720 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 0
Study 18019739 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride hydrochloride
Number of subjects: 18
Study 18019739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 18
Study 16268972 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal intake
Number of subjects: 12
Study 12383665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel
Number of subjects: 892
Study 12383665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel (more than 3.5 applicators per working day)
Number of subjects: 892
Study 12383665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel (less than 3.5 applicators per working day)
Number of subjects: 892
Study 12383665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 892
Study 10094160 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 0
Study 10094160 — intervention group
Group type: COMPARATOR
Intervention: Upright faces
Number of subjects: 0
Study 8920704 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb high-titre vaccine (EZ-HT,5m)
Number of subjects: 0
Study 8920704 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz standard measles vaccine (SW-STD,10m)
Number of subjects: 0
Study 8920704 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz high-titre vaccine (SW-HT,5m)
Number of subjects: 0
Study 8920704 — intervention group
Group type: COMPARATOR
Intervention: High-titre vaccines (EZ-HT and SW-HT)
Number of subjects: 0
Study 2012902 — intervention group
Group type: EXPERIMENTAL
Intervention: Same hearing aid system on two occasions
Number of subjects: 56
Study 2012902 — intervention group
Group type: EXPERIMENTAL
Intervention: Two acoustically different aids on two occasions
Number of subjects: 56
Study 2012902 — intervention group
Group type: COMPARATOR
Intervention: Comparison of two NHS hearing aid systems
Number of subjects: 56
Study 6807524 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 155
Study 6807524 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 155
Study 6807524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 155
Study 31106381 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly Cycling Work Roster (RCWR)
Number of subjects: 302
Study 31106381 — intervention group
Group type: COMPARATOR
Intervention: Extended Duration Work Roster (EDWR)
Number of subjects: 302
Study 28693531 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-needling acupuncture and medicinal cake-separated moxibustion
Number of subjects: 130
Study 28693531 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 130
Study 25393983 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical group
Number of subjects: 42
Study 25393983 — intervention group
Group type: COMPARATOR
Intervention: Macrosurgical group
Number of subjects: 42
Study 25393983 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study 23404832 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFESTYLE
Number of subjects: 240
Study 23404832 — intervention group
Group type: COMPARATOR
Intervention: USUAL CARE
Number of subjects: 240
Study 21992490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) injection 0.015%
Number of subjects: 91
Study 21992490 — intervention group
Group type: COMPARATOR
Intervention: Limbal conjunctival autograft transplantation (LCAT)
Number of subjects: 91
Study 19517895 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg Dexmethsone tablets (test formulation)
Number of subjects: 24
Study 19517895 — intervention group
Group type: COMPARATOR
Intervention: 4 mg tablets of the originator product (reference formulation)
Number of subjects: 24
Study 17604592 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin adjuvant to ongoing opioid treatment (group GO)
Number of subjects: 75
Study 17604592 — intervention group
Group type: COMPARATOR
Intervention: Opioid monotherapy (group OO)
Number of subjects: 75
Study 15555792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution (TDD) group treated according to volumetric preload endpoint (intrathoracic blood volume) obtained by invasive haemodynamic monitoring
Number of subjects: 50
Study 15555792 — intervention group
Group type: COMPARATOR
Intervention: Control group resuscitated according to the Baxter formula (4 ml/kg BW/% BSA burn)
Number of subjects: 50
Study 15555792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 50
Study 11173893 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation with standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.) for 14 days
Number of subjects: 120
Study 11173893 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 120
Study 11173893 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation with standard triple therapy
Number of subjects: 120
Study 9493716 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration (exact dosage and duration not specified)
Number of subjects: 0
Study 9493716 — intervention group
Group type: COMPARATOR
Intervention: Light exposure
Number of subjects: 0
Study 9272896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visits during pregnancy
Number of subjects: 1139
Study 9272896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visits during pregnancy and the first 2 years of the child's life
Number of subjects: 1139
Study 2241050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular and subcutaneous prilocaine with adrenaline
Number of subjects: 0
Study 2241050 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27947 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 8
Study 27947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30801621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (AP)
Number of subjects: 250
Study 30801621 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation therapy (AC)
Number of subjects: 250
Study 28069663 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic cybercycling PE curriculum (7-week intervention, 2 times per week, 30-40 minutes per session)
Number of subjects: 103
Study 28069663 — intervention group
Group type: COMPARATOR
Intervention: Standard nonaerobic PE (control period)
Number of subjects: 103
Study 26045340 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab plus gemcitabine and cisplatin
Number of subjects: 1093
Study 26045340 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin
Number of subjects: 1093
Study 22188329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric argon plasma for 2 min daily
Number of subjects: 46
Study 22188329 — intervention group
Group type: COMPARATOR
Intervention: Argon gas (placebo)
Number of subjects: 46
Study 21536968 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure
Number of subjects: 24
Study 21536968 — intervention group
Group type: COMPARATOR
Intervention: No SHS exposure (Control)
Number of subjects: 24
Study 19507407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C with metabolites (Ester-C)
Number of subjects: 0
Study 19507407 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 0
Study 17535146 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an individually tailored exercise program administered twice daily from hospital admission to discharge
Number of subjects: 236
Study 17535146 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 236
Study 15519089 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5 (sodium hyaluronate 2.3%)
Number of subjects: 140
Study 15519089 — intervention group
Group type: COMPARATOR
Intervention: Amvisc Plus (sodium hyaluronate 1.6%)
Number of subjects: 140
Study 11509774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro ThermAblator (HTA)
Number of subjects: 276
Study 11509774 — intervention group
Group type: COMPARATOR
Intervention: rollerball
Number of subjects: 276
Study 9739992 — intervention group
Group type: COMPARATOR
Intervention: No fatigue
Number of subjects: 0
Study 9739992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 0
Study 8072075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 20 micrograms prostaglandin E1 with 10 mg procaine
Number of subjects: 24
Study 8072075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 20 micrograms prostaglandin E1 with 20 mg procaine
Number of subjects: 24
Study 3062268 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 0
Study 3062268 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31383448 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 31
Study 31383448 — intervention group
Group type: EXPERIMENTAL
Intervention: Seed acupressure
Number of subjects: 31
Study 28454831 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisafe mhealth application
Number of subjects: 413
Study 28454831 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 413
Study 25256813 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third dose bacillus Calmette‐Guérin maintenance therapy every 6 months (3 weekly instillations)
Number of subjects: 0
Study 25256813 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third dose bacillus Calmette‐Guérin maintenance therapy every 3 months (2 weekly instillations)
Number of subjects: 0
Study 25256813 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third dose bacillus Calmette‐Guérin maintenance therapy
Number of subjects: 0
Study 23253774 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-interventional antibiotic prophylaxis (1.2 g amoxicillin/clavulanic acid during stent insertion)
Number of subjects: 95